We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 116% below its sector, cheaper than its peers on earnings.
Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based in Solna, Sweden, that specializes in the creation, manufacturing, and distribution of biosimilar medications. The company's development pipeline includes Xlucane, a ranibizumab biosimilar presently undergoing pivotal Phase III clinical trials. This therapeutic candidate is being evaluated for the treatment of several serious eye conditions, including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. In its earlier, preclinical stages, Xbrane is progressing a range of biosimilars: Xcimzane: Targeting autoimmune diseases such as rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, psoriasis, and Crohn's disease. Xoncane: Designed for acute lymphocytic leukemia. Spherotide: Intended for prostate cancer, breast cancer, endometriosis, and uterine myoma. Xdivane: Developed for various cancers, including melanoma, lung cancer, head and throat cancer, bladder cancer, urinary tract cancer, and renal cell carcinoma. Moreover, Xbrane has established a strategic partnership with STADA Arzneimittel AG. This collaboration aims to explore and potentially pursue joint development and commercialization opportunities for its preclinical biosimilar candidates, Xcimzane and Xdivane.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save XBRANE.ST and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
